Mydecine Innovations Group MYCO MYCOF, a biotech company in the psychedelics space, announced on Wednesday the launch of a virtual drug discovery program that will use artificial intelligence and machine learning to inform its drug discovery process.
“The in-silico program will enable the company to more rapidly screen hundreds of thousands of new molecules without the need to produce them,” said the company in a press release.
The program will be run in partnership with the University of Alberta.
By simulating chemical compounds in a computer interface, researchers can allocate their physical resources for more complex research, while leaving the AI to virtually produce and select new molecules worth researching in the lab.
“As the next evolution of drug discovery progresses forward, we strongly believe that this new age will be fully led by artificial intelligence and machine learning,” said Mydecine CEO Josh Bartch.
The program will be led by Dr. Khaled Barakat, a computer-aided drug development expert and assistant professor of pharmacy and pharmaceutical sciences at the University of Alberta.
Photo by L N on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!